
Autolus Therapeutics (AUTL) Stock Forecast & Price Target
Autolus Therapeutics (AUTL) Analyst Ratings
Bulls say
Autolus Therapeutics is developing an advanced portfolio of programmed T-cell therapies, utilizing innovative technologies to enhance the properties of T-cells for personalized and effective treatment of cancer. The company's diverse pipeline and strong clinical results position them well for future growth and success in the competitive biopharmaceutical market. Additionally, with increasing recognition and support for CAR-T therapy, Autolus is well-positioned to capitalize on the potential of this innovative treatment approach, making it a promising investment opportunity.
Bears say
Autolus Therapeutics is facing stiff competition in the CAR-T space from established players like Novartis and Gilead, as well as upcoming technologies such as allogeneic CAR-T therapies. Their lead product, Aucatzyl, has received FDA approval for r/r B-cell acute lymphoblastic leukemia (B-ALL) but has limited market potential due to its rare incidence. Their potential move into the frontline consolidation setting and expansion into other indications is still years away, with potential changes in clinical guidelines and practice patterns still uncertain. Additionally, the company's financial outlook for the near term is softer than expected, with projected sales and cash on hand not aligning with estimates by analysts. This, combined with potential challenges in patent protection and regulatory approval, leads to a negative outlook on Autolus Therapeutics' stock.
This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Autolus Therapeutics (AUTL) Analyst Forecast & Price Prediction
Start investing in Autolus Therapeutics (AUTL)
Order type
Buy in
Order amount
Est. shares
0 shares